Clinical trial NCT00104897 (phase 2, status: completed)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: tanespimycin
SMILES: [H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)C(C)=C([H])[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(NCC=C)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed malignant melanoma

               -  Metastatic (M1a, M1b, or M1c) disease

          -  Measurable disease by clinical exam, x-ray, CT scan, or MRI

          -  Must have documented disease progression at 2 time points separated by ≥ 6 months

               -  Pre-existing visceral lesions or the appearance of new visceral lesions allowed

               -  New skin disease amenable to surgery not allowed

          -  No primary brain tumors or brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

        Hepatic

          -  Bilirubin normal

          -  ALT and AST ≤ 1.5 times upper limit of normal

          -  No chronic liver disease

          -  No known hepatitis B or C positivity

        Renal

          -  Creatinine < 130 mmol/L OR

          -  Creatinine clearance > 60 mL/min

        Cardiovascular

          -  No symptomatic congestive heart failure

          -  No myocardial infarction within the past 6 months

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No transient ischemic attack

          -  No stroke or peripheral vascular disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for 4 weeks before, during, and for
             6 months after study participation

          -  No ongoing or active infection

          -  No diabetes mellitus with evidence of severe peripheral vascular disease or ulcers

          -  No history of allergy to eggs

          -  No known HIV positivity

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other uncontrolled illness

          -  No other malignancy except adequately treated cone-biopsied carcinoma in situ of the
             cervix or basal cell or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 4 weeks since prior immunotherapy

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

        Endocrine therapy

          -  More than 4 weeks since prior endocrine therapy

          -  Concurrent steroids allowed provided they are given at the lowest possible maintenance
             dose

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy unless administered for palliative care

          -  Concurrent radiotherapy allowed provided it is administered as a single fraction for
             bone pain OR as indicated for palliative care

        Surgery

          -  Not specified

        Other

          -  Recovered from all prior therapy

               -  Alopecia allowed

          -  No concurrent therapeutic anticoagulation with warfarin

               -  Concurrent prophylactic warfarin for central line maintenance allowed provided
                  INR is checked regularly until stable

               -  Concurrent low-molecular weight heparin allowed

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational drugs